Perrigo’s Record OTC Sales Tempered By Rising Costs Of Doing Business
This article was originally published in The Tan Sheet
Executive Summary
Record OTC drug sales helped boost Perrigo's revenue 29 percent in its latest earnings period, but the rising costs of doing business dragged down margins and forced the company to lower its fiscal 2009 earnings guidance
You may also be interested in...
Perrigo Strives To Stand Out Against Incoming Private Label Competition
Even as Perrigo products face the prospect of increasingly crowded segments, the company likes where it stands among private label competition
Perrigo Strives To Stand Out Against Incoming Private Label Competition
Even as Perrigo products face the prospect of increasingly crowded segments, the company likes where it stands among private label competition
Perrigo Strives To Stand Out Against Incoming Private Label Competition
Even as Perrigo products face the prospect of increasingly crowded segments, the company likes where it stands among private label competition